Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a ...

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its price objective reduced by research analysts at The Goldman Sachs Group from $28.00 to $24.00 in a research note issued to investors on ...

Q4 2024 Earnings Call Transcript February 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

In a report released today, Richard Law CFA from Goldman Sachs maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research ...

Jon Congleton; Chief Executive Officer, Director; Mineralys Therapeutics Inc. David Rodman; Chief Medical Officer ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

Highlights,Mineralys Therapeutics' stock opened at $10.15, reflecting recent market adjustments.,Executive transactions ...

RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has... ByInvesting.com ...

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

After hours: February 7 at 4:04:44 PM EST Loading Chart for MLYS ...